DNA Methylation Biomarker Testing

High‑Performance DNA Methylation Biomarker Testing – From Single Locus to Whole Epigenome

If you are searching for methylation biomarker testing, you likely need to detect, quantify, and validate DNA methylation changes associated with cancer early detection, liquid biopsy monitoring, disease subtyping, or epigenetic drug response prediction. Methylation biomarkers (e.g., promoter hypermethylation of tumor suppressors, differentially methylated regions) offer high stability and tissue specificity. Our laboratory provides comprehensive methylation analysis services – from targeted bisulfite pyrosequencing and methylation‑specific PCR (MSP) to genome‑wide methylation arrays (EPIC v2.0), whole‑genome bisulfite sequencing (WGBS), and reduced representation bisulfite sequencing (RRBS) – with single‑base resolution, low input requirements, and rigorous bioinformatics. We support discovery, validation, and clinical translation.

What We Detect – Full Methylation Biomarker Scope

We do not simply report “methylated or not”. Our platform includes bisulfite pyrosequencing for quantitative methylation analysis of specific CpG sites (e.g., promoters of MGMT, SEPT9, RASSF1A) with linearity over 0‑100% methylation and standard deviation <5%. For high‑throughput screening of known biomarkers, we offer multiplex methylation‑specific PCR (MSP) and quantitative MSP (qMSP) with detection limits as low as 0.1% methylated alleles in a background of unmethylated DNA. For genome‑wide discovery, we use Illumina Infinium MethylationEPIC v2.0 BeadChip (>850,000 CpG sites) and whole‑genome bisulfite sequencing (WGBS) at 30x coverage to capture all CpGs, non‑CpG methylation, and allele‑specific methylation. For limited sample amounts (e.g., cfDNA, FFPE, microdissected tissue), we perform RRBS (reduced representation bisulfite sequencing) requiring as little as 10‑50 ng DNA while covering ~3 million CpG‑rich regions. Our targeted bisulfite amplicon sequencing (bisulfite‑seq) can profile up to 500 amplicons (hundreds of CpGs per amplicon) with deep coverage (>1000x), ideal for validation cohorts. We also offer cell‑free DNA (cfDNA) methylation analysis for non‑invasive cancer detection, with digital droplet bisulfite PCR (ddBisPCR) achieving absolute quantification of methylated copies down to 0.01% variant allele fraction.

Key parameters and deliverables we routinely provide:
- Methylation level (β‑value or %) at each CpG site or region – from 0% (unmethylated) to 100% (fully methylated).
- Differentially methylated positions (DMPs) and regions (DMRs) – statistical significance (FDR <0.05) and methylation difference (Δβ).
- Classification scores (e.g., methylation score, methylation index) for predefined biomarker panels – for diagnostic or prognostic use.
- Concordance with reference samples and technical reproducibility (R² >0.99) – across replicates.
- Limit of detection for methylated allele in liquid biopsy (down to 0.01‑0.05%) – using ddPCR or targeted deep sequencing.
- Epigenetic age (Horvath clock, PhenoAge, GrimAge) from methylation data – for biological age estimation.
- Cell type deconvolution (e.g., immune cell fractions) from tissue/cfDNA methylation profiles.
- Pathway and functional enrichment of DMRs (e.g., promoter, enhancer, gene body annotation).

How Deep We Go – Single‑Molecule Methylation, cfDNA Haplotyping, and Clinical Validation

Most routine methylation labs stop at array‑based β‑values or MSP positivity. We offer single‑molecule methylation analysis using long‑read nanopore sequencing (Oxford Nanopore) to directly detect 5mC and 5hmC without bisulfite conversion, preserving haplotype‑specific methylation patterns. For liquid biopsy applications, we perform multiplex bisulfite amplicon sequencing with unique molecular identifiers (UMIs) to achieve 0.01% detection limit for methylated ctDNA in plasma, with absolute quantification of methylated copies per mL. We also provide methylation‑based minimal residual disease (MRD) monitoring using patient‑specific methylation signatures identified from primary tumor WGBS. Our targeted methylation panels for common cancers (e.g., colon, lung, breast, prostate) are designed from large‑scale public databases (TCGA, GEO) and validated in our own clinical cohort. We support regulatory‑grade validation following CLIA and ISO 15189 guidelines for in vitro diagnostic development.

Advanced capabilities include:
- Single‑cell DNA methylation analysis (scBS‑seq, scWGBS) for rare populations or circulating tumor cells.
- Epigenetic clocks for specific tissues or diseases – custom training on your own data.
- Integration of methylation with transcriptomic and proteomic data – for multi‑omics biomarker models.
- Automatic reporting pipeline including statistical analysis, volcano plots, heatmaps, and DMR annotations.
- Methylation data imputation (using reference panels) for missing CpGs – to harmonize different array versions.
- Analysis of methylation quantitative trait loci (meQTLs) using matched genotype data.
- Machine learning for biomarker classifier building (random forest, support vector machine, logistic regression) with cross‑validation.

We routinely achieve technical specifications: bisulfite conversion efficiency >99.5%; array call rate >99%; WGBS coverage >30x for human genome; RRBS coverage >10x per CpG; sensitivity of methylated ctDNA detection as low as 0.01% (5 copies/mL plasma). All methods follow guidelines from the International Human Epigenome Consortium (IHEC) and FDA biomarker qualification best practices.

Why Choose Our Methylation Biomarker Testing – Key Advantages

1. ISO/IEC 17025:2017 accredited and CLIA‑ready workflows – fully documented for translational and clinical research.
2. Multi‑platform flexibility (array, WGBS, RRBS, targeted amplicon, long‑read, ddPCR) – we match technology to your sample type, budget, and sensitivity needs.
3. Ultra‑sensitive detection of circulating methylated DNA down to 0.01% allele frequency – essential for early detection and MRD.
4. Comprehensive bioinformatics from raw data to biological interpretation (DMRs, pathways, epigenetic clocks, deconvolution) – we do not leave you with just a file.
5. Proven experience with over 1,000 methylation biomarker projects – including successful validations in colorectal, lung, breast, and pan‑cancer panels.
6. Fast turnaround with full data transparency – targeted methylation panel (10‑50 targets, 96 samples) in 5‑7 business days; genome‑wide array (24 samples) in 7‑10 business days; WGBS (1‑4 samples) in 12‑15 business days. You receive raw intensity files, methylation calls, QC metrics, and a comprehensive statistical report.
7. Custom panel design for novel markers or species – we design bisulfite primers and amplicons within 2‑3 weeks.
8. Competitive pricing for complete methylation biomarker discovery and validation packages – bundling discovery (array/WGBS), custom panel design, and validation (bisulfite amplicon sequencing) costs 35% less than piecemeal services.

We have successfully supported over 50 clinical validation studies for epigenetic diagnostics, with publications in high‑impact journals. Our team includes PhD epigeneticists, bioinformaticians, and molecular biologists dedicated to translational epigenomics.

Ready to Identify or Validate Your Methylation Biomarkers?

Provide your sample type (tissue, blood, plasma, FFPE), the disease context or biological question, and the desired analysis (e.g., “discovery of novel DMRs for early pancreatic cancer”, “validation of a 5‑gene methylation panel in serum”). We will provide a free technical consultation, a tailored experimental design, and a fixed‑price quote. Whether you need a single biomarker methylation check or a full‑scale multi‑cohort validation, we deliver deep, accurate, and clinically actionable DNA methylation biomarker testing tailored to your precision medicine application.